For patients with hormone receptor-positive, HER2-negative (HR+/HER2−) advanced breast cancer, the combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with endocrine therapies has revolutionized treatment. This evidence concerns the gene ERBB2 and breast cancer.